<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618200</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL15_0100</org_study_id>
    <nct_id>NCT02618200</nct_id>
  </id_info>
  <brief_title>Creation of an Image Database for the Development of a Computer Aided Diagnostic (CAD) System in Patients With Prostate Cancer</brief_title>
  <acronym>Echo-CAD</acronym>
  <official_title>Creation of a Multimodality Image Database (MRI + Ultrasound) for the Development of a Computer Aided Diagnostic (CAD) System in Patients With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is currently detected by ultrasound-guided biopsy. Computer-aided diagnostic
      (CAD) systems based on multiparametric MRI are now capable of detecting most aggressive
      cancer foci non-invasively, but additional progress is needed for the technique to be
      accepted in clinical practice. We hypothesize that combining MRI and ultrasound imaging can
      improve the detection of cancerous tumors. As a first step in this direction, we need to
      create a database with MR images, 3D ultrasound images, and corresponding histopathology
      results, in patients treated by radical prostatectomy for prostate cancer. This is the
      purpose of the present study.

      In a later stage (outside the scope of this study), we will be learning how to combine these
      images to best recognize cancerous tumors, we will use that knowledge to develop a new CAD
      system, and we will assess the performance of the new CAD. We expect this future system to
      improve the detection of prostate cancer and to reduce the number of patients requiring
      biopsy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Obtention of 3D ultrasound images</measure>
    <time_frame>the day before radical prostatectomy</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>3D prostate ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3D prostate ultrasound will be performed in patients the day before radical prostatectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3D prostate ultrasound</intervention_name>
    <arm_group_label>3D prostate ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient referred for radical prostatectomy

          -  Patient with multiparametric prostate MRI (3T) performed in our institution (Edouard
             Herriot Hospital) in the year preceding the surgery

          -  Informed consent signed

          -  Patient affiliated to the French Health Insurance system

        Exclusion Criteria:

          -  History of prostatic surgery or radiation therapy (prostatic or pelvic)

          -  History of hormone therapy for prostate cancer

          -  Previous surgery of the abdomino-perineal region, or other contraindication for
             transrectal ultrasound

          -  Patient on protection of the court, under supervision or under trusteeship

          -  Inability to express a consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olivier ROUVIERE, MD, PhD</last_name>
    <phone>+33 4 72 11 09 51</phone>
    <email>olivier.rouviere@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fanny CROS, CRA</last_name>
    <phone>+33 4 72 11 04 00</phone>
    <email>fanny.cros@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HÃ´pital Edouard Herriot - Service Service de radiologie</name>
      <address>
        <city>LYON cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier ROUVIERE, MD, PhD</last_name>
      <phone>+33 4 72 11 09 51</phone>
      <email>olivier.rouviere@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Fanny CROS, CRA</last_name>
      <phone>+33 4 72 11 04 00</phone>
      <email>fanny.cros@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier ROUVIERE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Computer-Aided Diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

